Drug news
CHMP recommends subcutaneous Velcade (Janssen) for Multiple Myeloma
The CHMP has granted a positive opinion recommending approval of subcutaneous administration of Velcade (bortezomib), from J&J Janssen Cilag, for patients with Multiple Myeloma. Subcutaneous bortezomib has fewer side effects and offers greater convenience for patients, with similar efficacy compared to intravenous bortezomib
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.